Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • New Therapeutic Targets in Cardiovascular Diseases (Upcoming)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI114780

Vasoactive intestinal peptide in human nasal mucosa.

J N Baraniuk, J D Lundgren, M Okayama, J Mullol, M Merida, J H Shelhamer, and M A Kaliner

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Disease, Bethesda, Maryland 20892.

Find articles by Baraniuk, J. in: JCI | PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Disease, Bethesda, Maryland 20892.

Find articles by Lundgren, J. in: JCI | PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Disease, Bethesda, Maryland 20892.

Find articles by Okayama, M. in: JCI | PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Disease, Bethesda, Maryland 20892.

Find articles by Mullol, J. in: JCI | PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Disease, Bethesda, Maryland 20892.

Find articles by Merida, M. in: JCI | PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Disease, Bethesda, Maryland 20892.

Find articles by Shelhamer, J. in: JCI | PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Disease, Bethesda, Maryland 20892.

Find articles by Kaliner, M. in: JCI | PubMed | Google Scholar

Published September 1, 1990 - More info

Published in Volume 86, Issue 3 on September 1, 1990
J Clin Invest. 1990;86(3):825–831. https://doi.org/10.1172/JCI114780.
© 1990 The American Society for Clinical Investigation
Published September 1, 1990 - Version history
View PDF
Abstract

Vasoactive intestinal peptide (VIP), which is present with acetylcholine in parasympathetic nerve fibers, may have important regulatory functions in mucous membranes. The potential roles for VIP in human nasal mucosa were studied using an integrated approach. The VIP content of human nasal mucosa was determined to be 2.84 +/- 0.47 pmol/g wet weight (n = 8) by RIA. VIP-immunoreactive nerve fibers were found to be most concentrated in submucosal glands adjacent to serous and mucous cells. 125I-VIP binding sites were located on submucosal glands, epithelial cells, and arterioles. In short-term explant culture, VIP stimulated lactoferrin release from serous cells but did not stimulate [3H]glucosamine-labeled respiratory glycoconjugate secretion. Methacholine was more potent than VIP, and methacholine stimulated both lactoferrin and respiratory glycoconjugate release. The addition of VIP plus methacholine to explants resulted in additive increases in lactoferrin release. Based upon the autoradiographic distribution of 125I-VIP binding sites and the effects on explants, VIP derived from parasympathetic nerve fibers may function in the regulation of serous cell secretion in human nasal mucosa. VIP may also participate in the regulation of vasomotor tone.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 825
page 825
icon of scanned page 826
page 826
icon of scanned page 827
page 827
icon of scanned page 828
page 828
icon of scanned page 829
page 829
icon of scanned page 830
page 830
icon of scanned page 831
page 831
Version history
  • Version 1 (September 1, 1990): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts